neuronetics transcranial magnetic stimulation rejected fda advisory panel today couple stories panel discussion recommendation try according one report majority panel made engineer several psychiatrists neurologists statistician problem rtms risks almost none biggest worry might accidentally spark seizure happen even patients treated problem neuronetics could prove benefit treated patients got little better patients underwent sham treatment according another source panel generally unimpressed company data showed slight statistical advantage depression symptoms dummy therapy six weeks treatment several panelists expressed dismay patients showed improvement depression scales minor improvement ones showed difference panel seems consensus primary analysis establish efficacy said thomas brott committee chairman perhaps reasonable person could question whether effect said brott neurologist mayo medical school jacksonville fla panel formally recommend fda whether machine approved agency scientists suggested public hearing also uneasy company results ann costello fda medical reviewer questioned whether mixed evidence effectiveness neuronetics studies contained clinically relevant information peter lurie deputy director public citizen health research group told panel neuronetics show device substantially equal standard many medical devices must meet fda approval focused fact patients actively treated machine showed mild improvement one three depression scales magnitude finding trivial clinical point view said interview maybe fda panel learned something vns approval